Inhibition of PERK pathway promotes TAMs M1 polarization and ER stress in Osteosarcoma cells hindering tumor progression
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115293 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Xiaobing Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Xinxiang Central Hospital, The Fourth Clinical College of Xinxiang Medical University, Xinxiang City 453000, China. Electr…. Hauptthemen laut MEDLINE: Osteosarcoma, eIF-2 Kinase, Tumor-Associated Macrophages, Bone Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, Xinxiang Central Hospital, The Fourth Clinical College of Xinxiang Medical University, Xinxiang City 453000, China. Electronic address: lwzyyx123@163.com.
- Department of Orthopedics, Xinxiang Central Hospital, The Fourth Clinical College of Xinxiang Medical University, Xinxiang City 453000, China.
- Sanya People's Hospital / West China (Sanya) Hospital, Sichuan University, Department of Orthopedics, Sanya City, 572032, China.
Zitieren
APA
Li, X., Guo, X., Wang, W., & Liu, P. (2025). Inhibition of PERK pathway promotes TAMs M1 polarization and ER stress in Osteosarcoma cells hindering tumor progression. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115293
Vancouver
Li X, Guo X, Wang W, Liu P. Inhibition of PERK pathway promotes TAMs M1 polarization and ER stress in Osteosarcoma cells hindering tumor progression. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115293
BibTeX
@article{Li2025,
author = {Li, Xiaobing and Guo, Xinjun and Wang, Wenbo and Liu, Panke},
title = {Inhibition of PERK pathway promotes TAMs M1 polarization and ER stress in Osteosarcoma cells hindering tumor progression},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115293}
}
EUVIMED